Dana-Farber Investigators Pinpoint Keys to Cell Therapy Response for Leukemia By Beth Dougherty 15 May, 2025
EGLN1 Protein May be a Possible Therapeutic Target in Rare Kidney Cancer By Beth Dougherty 14 Apr, 2025
Dana-Farber Launches Center for RAS Therapeutics to Target the RAS Oncogene in Cancer By Admin 6 Jan, 2025
First Clinical Trial of “Memory Like” Natural Killer Cells in Ovarian Cancer Opens at Dana-Farber By Admin 15 Nov, 2024
